MCM5 and ovarian adenocarcinoma: In conclusion, in the present study, we have investigated for the first time MCM-2 and MCM-5 expression in LMP tumours and ovarian adenocarcinomas in relation with clinicopathologic parameters, cell cycle modulators and patients’ survival.